John D. Mills

ResApp Health Ltd. engages in the research and commercial development of ResApp technology for the purpose of providing health care solutions for respiratory disease. The technology is based on a machine learning algorithm that uses sound alone without the need for additional hardware to diagnose and measure the severity of a respiratory condition. ResApp’s core technology uses sound to diagnose respiratory diseases including pneumonia, bronchiolitis, bronchitis, chronic obstructive pulmonary disease and asthma. The company was founded on September 13, 2000 by John Majewski and is headquartered in Brisbane, Australia.

Cavidi AB develops and manufactures IVD tests for detection and monitoring of viral diseases. Its ExaVir product series utilizes the HIV reverse transcriptase enzyme to measure viral load and drug susceptibility. The company develops front-line assays for various polymerase enzymes of interest to pharmaceutical, medical, and veterinary research. It offers hospitals, private laboratories, pharmaceutical industries, and research institutions worldwide. Cavidi was founded in 1984 and is headquartered in Uppsala, Sweden.

Tissupath Pty Ltd. operates as a specialist pathology practice firm. The firm's services include reports, turnaround times for reports, reports tailored to individual clinicians, double reporting of all biopsies and volumetric mapping for selected malignancies. The company was founded by John Mills in 2004 and is headquartered in Mount Waverley, Australia.

The Macfarlane Burnet Institute For Medical Research & Public Health Ltd. provides medical research and public health services. Its programs include maternal health, disease elimination, behaviors and health risks, health security, and healthy ageing. The organization also focuses on women's and children's health; alcohol, other drugs and harm reduction; sexual and reproductive health; and young people's health. The organization was founded in 1986 headquartered in Melbourne, Australia.

CSL Innovation Pty Ltd. develops pharmaceutical products. The firm also develops human antibody inhibitors of the granulocyte-macrophage colony stimulating factor receptor alpha subunit, GM-CSFRa, for potential therapeutic use in inflammatory diseases. The company was founded in 1986 and is headquartered in Richmond, Australia.

GBS Venture Partners Pty Ltd (GBS Venture Partners) is a venture capital firm founded in 1996 by Helen Brigitte Smith and Geoff E.D Brooke. The firm is headquartered in Melbourne.